{"id":945263,"date":"2026-03-18T07:11:10","date_gmt":"2026-03-18T11:11:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/"},"modified":"2026-03-18T07:11:10","modified_gmt":"2026-03-18T11:11:10","slug":"fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/","title":{"rendered":"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026"},"content":{"rendered":"
\n

RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company\u2019s financial and business results.<\/p>\n\n\n\n\n\n\n\n\n
\n Conference Call & Webcast Detail:<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\n\u00a0<\/td>\nTuesday, March 24, 2026<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n\u00a0<\/td>\n8:30 a.m. Eastern Time<\/td>\n<\/tr>\n
\n Webcast Link:<\/strong>\n <\/td>\n\u00a0<\/td>\n\n https:\/\/edge.media-server.com\/mmc\/p\/3crq898e<\/a>\n <\/td>\n<\/tr>\n
\n Participant Link:<\/strong>\n <\/td>\n\u00a0<\/td>\n\n https:\/\/register-conf.media-server.com\/register\/BIb7d9f04377fd4b9cb7b005d167555402<\/a>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n

To access the live webcast link, log onto\u00a0www.fennecpharma.com<\/a> and proceed to the News & Events\/Event Calendar page under the Investors & Media heading. Please connect to the company\u2019s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.<\/p>\n

\n About\u00a0Fennec Pharmaceuticals<\/strong>
\n
Fennec Pharmaceuticals Inc.\u00a0is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK\u00ae<\/sup>\u00a0to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in\u00a0September 2022\u00a0and\u00a0European Commission\u00a0approval in\u00a0June 2023\u00a0and\u00a0United Kingdom\u00a0(U.K.) approval in\u00a0October 2023\u00a0under the brand name PEDMARQSI.<\/p>\n

In\u00a0March 2024, Fennec entered into an exclusive licensing agreement under which\u00a0Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize\u00a0PEDMARQSI\u00ae<\/sup>\u00a0in\u00a0Europe,\u00a0U.K.,\u00a0Australia\u00a0and\u00a0New Zealand. PEDMARQSI is now commercially available in the\u00a0U.K.\u00a0and\u00a0Germany.<\/p>\n

PEDMARK has received Orphan Drug Exclusivity in the\u00a0U.S.\u00a0and.; PEDMARQSI has received Pediatric Use Marketing Authorization in\u00a0Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the\u00a0U.S.\u00a0and internationally.<\/p>\n

For more information, please visit\u00a0www.fennecpharma.com<\/a>\u00a0and follow on\u00a0LinkedIn<\/a>.<\/p>\n

\n For further information, please contact:<\/strong>\n <\/p>\n

\n Investors:<\/strong>
\n
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299<\/p>\n

\n Corporate and Media:<\/strong>
\n
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company\u2019s financial and business results. Conference Call & Webcast Detail: \u00a0 \u00a0 \u00a0 Date: \u00a0 Tuesday, March 24, 2026 Time: \u00a0 8:30 a.m. Eastern Time Webcast Link: \u00a0 https:\/\/edge.media-server.com\/mmc\/p\/3crq898e Participant Link: \u00a0 https:\/\/register-conf.media-server.com\/register\/BIb7d9f04377fd4b9cb7b005d167555402 \u00a0 To access the live webcast link, log onto\u00a0www.fennecpharma.com and proceed to the News & Events\/Event Calendar page under the Investors & … <\/p>\n

Continue reading “Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-945263","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company\u2019s financial and business results. Conference Call & Webcast Detail: \u00a0 \u00a0 \u00a0 Date: \u00a0 Tuesday, March 24, 2026 Time: \u00a0 8:30 a.m. Eastern Time Webcast Link: \u00a0 https:\/\/edge.media-server.com\/mmc\/p\/3crq898e Participant Link: \u00a0 https:\/\/register-conf.media-server.com\/register\/BIb7d9f04377fd4b9cb7b005d167555402 \u00a0 To access the live webcast link, log onto\u00a0www.fennecpharma.com and proceed to the News & Events\/Event Calendar page under the Investors & … Continue reading "Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T11:11:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026\",\"datePublished\":\"2026-03-18T11:11:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/\"},\"wordCount\":393,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/\",\"name\":\"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=\",\"datePublished\":\"2026-03-18T11:11:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/","og_locale":"en_US","og_type":"article","og_title":"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company\u2019s financial and business results. Conference Call & Webcast Detail: \u00a0 \u00a0 \u00a0 Date: \u00a0 Tuesday, March 24, 2026 Time: \u00a0 8:30 a.m. Eastern Time Webcast Link: \u00a0 https:\/\/edge.media-server.com\/mmc\/p\/3crq898e Participant Link: \u00a0 https:\/\/register-conf.media-server.com\/register\/BIb7d9f04377fd4b9cb7b005d167555402 \u00a0 To access the live webcast link, log onto\u00a0www.fennecpharma.com and proceed to the News & Events\/Event Calendar page under the Investors & … Continue reading \"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-18T11:11:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026","datePublished":"2026-03-18T11:11:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/"},"wordCount":393,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/","name":"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=","datePublished":"2026-03-18T11:11:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDE5NiM3NDkxMzcxIzIwODk4NTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-24-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=945263"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945263\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=945263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=945263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=945263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}